Lazabemide monohydrochloride

L-threo Lysosphingomyelin (d18:1) (L-threo-Sphingosylphosphorylcholine) is an endogenous bioactive sphingolipid. L-threo Lysosphingomyelin (d18:1) is a potent S1P receptor agonist with EC 50 s of 19.3, 131.8, and 313.3 nM for hS1P 1 , hS1P 3 , and

Cell Line Origin Human Neuroblastoma Bone Marrow Metastasis Cell Line Description Established by Seeger et al., (1977) from neuroblastoma cells in the bone marrow of a 2-year-old male with clinical Stage IV neuroblastoma.

An internal standard for the quantification of latanoprost (free acid) by GC- or LC-MS.

An internal standard for the quantification of latanoprost (free acid) by GC- or LC-MS.

An internal standard for the quantification of latanoprost (free acid) by GC- or LC-MS.

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

An internal standard for the quantification of Latanoprost by GC- or LC-MS.

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM.

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM.

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM.

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM.

Lazabemide is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) with Ki value of 7.9 nM.